[High-dose Methotrexate/leucovorin Adjuvant Chemotherapy of Osteogenic Sarcoma: Biochemical Effects in DNA-synthesis of Bone Marrow Cells (author's Transl)]

Overview

Journal Blut

Specialty Hematology

Date 1978 Jun 20

PMID 306851

Citations 2

Authors

H Sauer

W Wilmanns

Affiliations

Soon will be listed here.

Abstract

DNA metabolism in bone marrow cells was measured under high-dose Methotrexate/Leucovorin adjuvant chemotherapy of a patient with primary amputation of his right leg because of osteogenic sarcoma. The biochemical data showed that there was no rescue effect of Leucovorin after 200 mg/kg Methotrexate. Corresponding to this "biochemical failure" of the rescue effect the patient died from the complications of a long and very severe bone marrow suppression. To improve the safety of this therapeutic regimen the intravenous injection and in some cases a higher dose of Leucovorin is recommended.

Citing Articles

Effect of methotrexate concentration and exposure time on mammalian cell survival in vitro.

Eichholtz H, Trott K Br J Cancer. 1980; 41(2):277-84.

PMID: 7370167 PMC: 2010205. DOI: 10.1038/bjc.1980.40.

[Multidrug chemotherapy of osteogenic sarcoma (author's transl)].

Prindull G Blut. 1979; 39(4):293-300.

PMID: 291443 DOI: 10.1007/BF01013224.

References

Wilmanns W . [Thymidine kinase in normal and leukemic myeloid cells]. Klin Wochenschr. 1967; 45(10):505-11. DOI: 10.1007/BF01716365. View

Lustig R, DeMare P, Kramer S . Adjuvant methotrexate in the radiotherapeutic management of advanced tumors of the head and neck. Cancer. 1976; 37(6):2703-8. DOI: 10.1002/1097-0142(197606)37:6<2703::aid-cncr2820370620>3.0.co;2-h. View

Hoffken K, Seeber S, Gallmeier W, Bruntsch U, Hossfeld D, SCHMIDT C . [Chemotherapy of malignant bone tumors]. Chirurg. 1977; 48(4):274-9. View

Sauer H, Jaenicke L . [Suppression of cytostatic effect of amethopterin (methotrexate) with methyltetrahydrofolic acid]. Blut. 1974; 28(5):321-6. DOI: 10.1007/BF01631519. View

SUTOW W, Gehan E, Vietti T, Frias A, Dyment P . Multidrug chemotherapy in pulmonary treatment of osteosarcoma. J Bone Joint Surg Am. 1976; 58(5):629-33. View

Jaffe N, Frei 3rd E, Traggis D, Watts H . Weekly high-dose methotrexate-citrovorum factor in osteogenic sarcoma: pre-surgical treatment of primary tumor and of overt pulmonary metastases. Cancer. 1977; 39(1):45-50. DOI: 10.1002/1097-0142(197701)39:1<45::aid-cncr2820390109>3.0.co;2-t. View

Vahrson H, Gorges K . [Experiences with enterally and parenterally applied leucovorin following therapy with high doses of methotrexate in malignant tumors (author's transl)]. Med Klin. 1976; 71(41):1720-3. View

Rosen G, Murphy M, Huvos A, Gutierrez M, Marcove R . Chemotherapy, en bloc resection, and prosthetic bone replacement in the treatment of osteogenic sarcoma. Cancer. 1976; 37(1):1-11. DOI: 10.1002/1097-0142(197601)37:1<1::aid-cncr2820370102>3.0.co;2-3. View

Bender R . Anti-folate resistance in leukemia: treatment with "high-dose" methotrexate and citrovorum factor. Cancer Treat Rev. 1975; 2(3):215-24. DOI: 10.1016/s0305-7372(75)80004-1. View

10.

Frei 3rd E . Methotrexate revisited. Med Pediatr Oncol. 1976; 2(3):227-41. DOI: 10.1002/mpo.2950020303. View

11.

Wilmanns W . [Dihydrofolate reductase and thymidine kinase in the bone marrow under the influence of folic acid antagonists]. Klin Wochenschr. 1967; 45(19):987-94. DOI: 10.1007/BF01746131. View

12.

Jaffe N . The potential of combined modality approaches for the treatment of malignant bone tumors in children. Cancer Treat Rev. 1975; 2(1):33-53. DOI: 10.1016/s0305-7372(75)80014-4. View

13.

Djerassi I, Kim J, Shulman K . High-dose methotrexate-citrovorum factor rescue in the management of brain tumors. Cancer Treat Rep. 1977; 61(4):691-4. View

14.

Sauer H, Wilmanns W . Cobalamin dependent methionine synthesis and methyl-folate-trap in human vitamin B12 deficiency. Br J Haematol. 1977; 36(2):189-98. DOI: 10.1111/j.1365-2141.1977.tb00639.x. View

15.

Pratt C, Shanks E, HUSTU O, Rivera G, Smith J, Kumar A . Adjuvant multiple drug chemotherapy for osteosarcoma of the extremity. Cancer. 1977; 39(1):51-7. DOI: 10.1002/1097-0142(197701)39:1<51::aid-cncr2820390110>3.0.co;2-t. View

16.

Jaenicke L, Wilmanns W . [FOLIC ACID METABOLISM AND ONE-CARBON UNITS]. Klin Wochenschr. 1963; 41:1030-8. DOI: 10.1007/BF01478089. View

17.

Djerassi I, Kim J, Nayak N, Ohanissian H, Adler S, Hsieh S . New "rescue" with massive doses of citrovorum factor for potentially lethal methotrexate toxicity. Cancer Treat Rep. 1977; 61(4):749-50. View

18.

Bleyer W . Methotrexate: clinical pharmacology, current status and therapeutic guidelines. Cancer Treat Rev. 1977; 4(2):87-101. DOI: 10.1016/s0305-7372(77)80007-8. View

19.

Djerassi I, Kim J . Methotrexate and citrovorum factor rescue in the management of childhood lymphosarcoma and reticulum cell sarcoma (non-Hodgkin's lymphomas): parolonged unmaintained remissions. Cancer. 1976; 38(3):1043-51. DOI: 10.1002/1097-0142(197609)38:3<1043::aid-cncr2820380302>3.0.co;2-u. View

20.

Frei 3rd E, Jaffe N, Tattersall M, Pitman S, Parker L . New approaches to cancer chemotherapy with methotrexate. N Engl J Med. 1975; 292(16):846-51. DOI: 10.1056/NEJM197504172921607. View